J&J Unit Fights Use Of New Topamax Label In Defect Suits

Law360, Philadelphia (March 5, 2014, 2:05 PM EST) -- A Johnson & Johnson unit said Tuesday that plaintiffs in a cluster of suits alleging that the anti-epilepsy drug Topamax caused birth defects had improperly asked a Pennsylvania judge to reconsider a decision over the admissibility of a 2011 label change strengthening warnings about risks to pregnant women.

Janssen Pharmaceuticals Inc. said that the Pennsylvania Supreme Court’s order in December nixing an appeal in Daniel v. Wyeth Pharmaceuticals — which dealt with the admissibility of labels that post-date a plaintiff’s use of a medication — did...
To view the full article, register now.